Alemtuzumab in the treatment of chronic lymphocytic lymphoma

References

• Rawstron AC, Kennedy B, Evans PA et al. Quantitation of minimal disease levels in chronic lymphocytic leukaemia using a sensitive flow cytometrc assay improves the prediction of outcome and can be used to optimize therapy. Blood98, 29–35 (2001).
   PubMed Web of Science ®Google Scholar
• Catovsky D, Richards S, Matutes E et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL 4 trial): a randomised controlled trial. Lancet370(9583), 230–239 (2007).
   PubMed Web of Science ®Google Scholar
• Keating MJ, O’Brien S, Albitar M et al. Early results of a chemoimmunotherapy regime of fludarabine, cyclophosphamide and rituximab as initial therapy for chronic lymphocytic leukaemia. J. Clin. Oncol.23(18), 4079–4088 (2005)
   PubMed Web of Science ®Google Scholar
• Hale G, Clark M, Waldmann H. Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukaemia following intravenous or subcutaneous routes of administration. Blood104, 948–955 (2004).
   PubMed Web of Science ®Google Scholar
• Mould DR, Baumann A, Kuhlmann J et al. Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukemia and its link to treatment response. Br. J. Clin. Pharmacol.64(3), 278–291 (2007).
   PubMed Web of Science ®Google Scholar
• Ginaldi L, De Martinis M, Matutes E et al. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk. Res.22, 185–191 (1998).
   PubMed Web of Science ®Google Scholar
• Lundin J, Kimby E, Bjorkholm M et al. Phase II trial of subcutaneous anti-CD 52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukaemia (B-CLL). Blood100, 768–773 (2002).
   PubMed Web of Science ®Google Scholar
• Mone AP, Cheney C, Banks AL et al. Alemtuzumab induces capase-independent cell death in human chronic lymphocytic leukaemia cells through a lipid raft-dependent mechanism. Leukemia20, 272–279 (2006).
   PubMed Web of Science ®Google Scholar
• Osterborg A, Dyer MJS, Bunjes D et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukaemia. European Study Group of CAMPATH-1H treatment in chronic lymphocytic leukaemia. J. Clin. Oncol.15, 1567–1574 (1997).
   PubMed Web of Science ®Google Scholar
• Keating MJ, Flinn I, Jain V et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood99, 3354–3361 (2002).
   Google Scholar
• Rai KR, Freter CE, Mercier RJ et al. Alemtuzumab in previously treated chronic lymphocytic leukaemia patients who also had received fludarabine. J. Clin. Oncol.23 (18), 3891–3897 (2002).
   Google Scholar
• Ferrajoli A, O’Brien SM, Cortes JE. Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer98, 773–778 (2003).
   PubMed Web of Science ®Google Scholar
• Moreton P, Kennedy B, Lucas G et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukaemia after alemtuzumab therapy is associated with prolonged survival. J. Clin. Oncol.23, 2971–2979 (2005).
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S Winkler D, Kröber A et al. Subcutaneous Campath-1H (alemtuzumab) in fludarabine refractory CLL; interim analysis of the CLL2H Study of the German CLL Study Group (GCLLSG). Blood104 (2004) (Abstract 478).
   Google Scholar
• Osterborg A, Fassas AS, Anagnostopoulos A et al. Humanized CD 52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. Br. J. Haematol.93, 151–153 (1996).
   PubMed Web of Science ®Google Scholar
• Hillmen P, Skotnicki AB, Robak T et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukaemia. J. Clin. Oncol.25(35), 5616–5623 (2007).
   PubMed Web of Science ®Google Scholar
• Rai KR, Peterson BL, Appelbaum FR et al. Fludarabine compared to chlorambucil as primary therapy for chronic lymphocytic leukaemia. N. Engl. J. Med.343, 1750–1757 (2000).
   PubMed Web of Science ®Google Scholar
• Robak T, Blonski JZ, Gora-Tybor J et al. Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective multicenter randomised trial of the Polish Adult Leukemia Group (PALG CLL2). Blood108, 473–479 (2006).
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Litchy S, Barton JH et al. Single agent rituxumab as first-line and maintenance treatment for patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a Phase II trial of the Minnie Pearl Cancer Research Network. J. Clin. Oncol.21, 1746–1751 (2003).
   PubMed Web of Science ®Google Scholar
• Dohner H, Fischer K, Bentz M et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood85, 580–589 (1995).
   PubMedGoogle Scholar
• Thornton PD, Hamblin M, Treleaven JG et al. High dose methylprednisolone in refractory chronic lymphocytic leukaemia. Leuk. Lymphoma34, 167–170 (1999).
   PubMed Web of Science ®Google Scholar
• Lozanski G, Heerema NA, Flinn IW et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukaemia with p53 mutations and deletions. Blood103, 3278–3281 (2004).
   PubMed Web of Science ®Google Scholar
• Osuji N, Del Giudice I, Matutes E et al. The efficacy of alemtuzumab for refractory chronic lymphocytic leukaemia in relation to cytogenetic abnormalities of p53. Haematologica90, 1435–1436 (2005).
   PubMed Web of Science ®Google Scholar
• Pettitt AR, Matutes E, Oscier D. Alemtuzumab in combination with high dose methylprednisolone: a rational approach for CLL patients with p53 defects. Leuk. Lymphoma46(Suppl.1), S92 (2005).
   Google Scholar
• Rai KR, Byrd JC, Peterson B et al. Alemtuzumab following fludarabine for previously untreated patients with chronic lymphocytic leukaemia (CLL). CALGB study 199901. Blood102, A676, 2506 (2003).
   Web of Science ®Google Scholar
• O’Brien SM, Kantarjian HM, Thomas DA et al. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukaemia. Cancer98, 2657–2663 (2005).
   Google Scholar
• Montillo M, Tedeschi A, Miqueleiz S et al. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukaemia. J. Clin. Oncol.24(15), 2337–2342 (2006).
   PubMed Web of Science ®Google Scholar
• Wendtner CM, Ritgen M, Schweighofer CD et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomised multicenter Phase III trial of the German CLL Study Group (GCLLSG). Leukemia18(6), 1093–1101 (2004).
   PubMed Web of Science ®Google Scholar
• Schweighofer M, Ritgen B, Eichorst R et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission. Long-term follow-up of a randomized Phase III trial of the German CLL study group (GCLLSG). Blood108, p14, a33 (2006).
   Google Scholar
• Gilleece MH, Dexter TM et al. Effect of Campath-1H antibody on human haemopoietic progenitors in vitro. Blood82, 807–812 (1993).
   PubMed Web of Science ®Google Scholar
• Montillo M, Miqueleiz S, Tedeschi A et al. Combined Fludarabine, Cyclophosphamide and Alemtuzumab (FCC), an active regimen for treated patients with chronic lymphocytic leukemia (CLL). Blood100, (2007) (Abstract 3133).
   Google Scholar
• Elter T, Borchmann P, Schulz H et al. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukaemia: results of a Phase II trial. J. Clin. Oncol.23, 7024–7031 (2005).
   PubMed Web of Science ®Google Scholar
• Faderl S, Thomas DA, O’Brien S et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood101, 3413–3415 (2003).
   PubMed Web of Science ®Google Scholar
• Wierda WG, O’Brien S, Faderl S et al. Combined cyclophosphamide, fludarabine, alemtuzumab and rituximab (CFAR), an active regimen for heavily treated patients with CLL. Blood108, p14, a31 (2006).
   Web of Science ®Google Scholar
• Piccaluga PP, Agostinelli C, Rigali S et al. Expression of CD52 in peripheral T-cell lymphoma. Haematologica92(4), 566–567 (2007).
   PubMed Web of Science ®Google Scholar
• Rodig SJ, Abramson JS, Pinkus GS et al. Heterogenous CD52 expression among haematologic neoplasms: implications for the use of alemtuzumab (Campath-1H). Clin. Cancer Res.12(23), 7174–7179 (2006).
   PubMed Web of Science ®Google Scholar
• Chang ST, Lu CL, Chuang SJ et al. CD52 expression in non-mycotic T and NK/T-cell lymphoma. Leuk. Lymphoma48(1), 117–121 (2007).
   PubMed Web of Science ®Google Scholar
• Dearden CE, Matutes E, Cazin B et al. High remission rate in T-cell prolymphocytic leukaemia with CAMPATH-1H. Blood98, 1721–1726 (2001).
   PubMed Web of Science ®Google Scholar
• Keating MJ, Cazin B, Coutre S et al. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J. Clin. Oncol.20, 205–213 (2002).
   PubMed Web of Science ®Google Scholar
• Dearden C, Matutes E, Cazin B et al. Very high response rates in previously untreated T-cell Prolymphocytic leukaemia patients receiving alemtuzumab (Campath-1H) therapy. Blood102, (2003) (Abstract 2378).
   Google Scholar
• Lundin J, Osterborg A, Brittinger G et al. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin’s lymphomas: a Phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin’s Lymphoma. J. Clin. Oncol.16, 3257–3263 (1998).
   PubMed Web of Science ®Google Scholar
• Kennedy GA, Seymour JF, Wolf M et al. Treatment of patients with advanced mycosis fungoides and Sezary syndrome with alemtuzumab. Eur. J. Haematol.71, 250–256 (2003).
   PubMed Web of Science ®Google Scholar
• Foukaneli T, Marsh J, Pettegell R et al. Sezary syndrome responds to treatment with Campath-1H. Blood98 (2001) (Abstract 556).
   Google Scholar
• Capalbo S, Delia M, Dargenio M et al. Mycosis fungoides/Sezary syndrome: a report of three cases treated with Campath-1H as salvage treatment. Med. Oncol.20, 389–396 (2003).
   PubMed Web of Science ®Google Scholar
• Porcu P, Mone A, Puhalla S et al. Durable complete response of the human T-cell leukemia virus (HTLV-1) viral load (VL) with alemtuzumab in refractory adult T-cell leukemia (ATL). J. Clin. Oncol.28(Suppl.16, Part I) (2005) (Abstract 6639).
   Google Scholar
• Enblad G, Hagberg H, Eriksson M et al. A pilot study of alemtuzumab (Anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphoma. Blood102 (2003) (Abstract 2384).
   Google Scholar
• Gallamini A, Zaja F, Patti C et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma; results of a GITIL (Gruppo Itaiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood110, 2316–2323 (2007).
   PubMed Web of Science ®Google Scholar
• Delgado J, Thomson K, Russell N et al. Results of alemtuzumab-based reduced-intensity allogenic transplantation for chronic lymphocytic leukaemia: a British Society of Blood and Marrow Transplantation Study. Blood107, 1724–1730 (2006)
   PubMed Web of Science ®Google Scholar
• Peggs KS, Mackinnon S, Williams CD et al. Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating dodor lymphocyte infusions for chemotherapy sensitive myeloma: limited efficacy of graft-versus-tumour activity. Biol. Blood Marrow Transplant.9, 257–265 (2003).
   PubMed Web of Science ®Google Scholar
• Faulkner RD, Craddock C, Byrne JL et al. BEAM-Campath reduced intensity allogenic stem cell transplantation for lymphoproliferative diseases: GvHD, toxicity and survival in 65 patients. Blood103, 428–434 (2004).
   PubMed Web of Science ®Google Scholar
• Peggs KS, Thomson K, Chopra R et al. Long term results of reduced intensity transplantation in multiply relapsed and refractory Hodgkins lymphoma: evidence of a therapeutically relevant graft-versus-lymphoma effect. Blood102, A694 (2003)
   Google Scholar
• Parker JE, Shah I, Pagliuca A et al. Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reduced-intensity conditioning compared with standard preparative regimens. Br. J. Haem.119, 144–154 (2002).
   PubMed Web of Science ®Google Scholar
• O’Brien S, Ravandi-kashani F, Wierda W et al. A randomized trial of Valaciclovir versus Valganciclovir to prevent CMV reactivation in patients with CLL receiving alemtuzumab. Blood106, 830 (2006) (Abstract 2960).
   Google Scholar
• Rezvany MR, Tehrani MJ, Karlsson C et al. Reconstitution of the T-cell repertoire following treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with B-cell chronic lymphocytic leukaemia. Br. J. Haem.135(4), 475–485 (2006).
   PubMedGoogle Scholar
• Wing MG, Moreau T, Greenwood J et al. Mechanism of first-dose cytokine release syndrome by CAMPATH-1H: involvement of CD16 (FcgammaRIII) and CD11a/CD18(LFA-1) on NK cells. J. Clin. Invest.98, 2819–2826 (1998).
   Google Scholar
• Lenihan DJ, Alencar AJ, Yang D et al. Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sezary syndrome. Blood104, 655–658 (2004).
   PubMed Web of Science ®Google Scholar
• Lundin J, Kennedy B, Dearden C et al. No cardiac toxicity associated with alemtuzumab therapy for mycosis fungoides/Sezary syndrome. Blood105, 4148–4149 (2005).
   PubMed Web of Science ®Google Scholar